Within3 is Committed to Providing the Most Relevant Information in the Industry

Clinical Decision Making

April 13, 2017 | White Paper

When optimally managed, the relationship between pharmaceutical organizations and healthcare professionals (HCPs) on the frontlines of patient care is bi-directional. A leading pharmaceutical organization’s joint medical affairs and commercial team, purposed with gaining insight and treatment perspectives about prescribing preferences and informational needs, was tasked with identifying an innovative approach to facilitating bi-directional discussions with leading clinicians around the country. This case study explains how they did it.

Read More

The 9 Ways Companies Engage Small Groups via Within3

March 02, 2017 | White Paper

Based on an analysis of hundreds of Within3 programs from around the world, this Whitepaper will outline the current trends of how companies are choosing to engage with small teams of payers, patients, physicians, caregivers, and more.
Read More

2016 Industry Trends In Online Discussion Meetings

October 26, 2016 | White Paper

It seems as if all things are online now – shopping, education, entertainment – it was only a matter of time before the life sciences industry followed suit. Life science companies are constantly tasked with engaging healthcare professionals in order to help with all aspects of a drug lifecycle. The advent of online discussion platforms has allowed companies to engage with these stakeholders more frequently and at lower costs.

Read More

Improving Speakers Bureau Communications

May 05, 2016 | White Paper

Modern technology has the ability to improve speakers bureau programs. At a high level, speakers bureau software can reduce costs and expertly organize and schedule dinner meetings, creating a strong foundation for effective and valuable programs. However, the challenges with existing programs has not allowed for the highest quality materials to be presented by the best educated speakers to the most extensive audiences.

The following white paper identifies three crucial communication challenges within a speakers bureau program and how to address them. 
Read More

505(b)(2) Drug Development Pathway

February 19, 2016 | White Paper

The 505(b)(2) regulatory pathway is one of three categories of new drug applications (NDA). While the application requires full safety and effectiveness reports, it gives the FDA permission to use data not gathered by the NDA applicant, avoiding unnecessary duplicate analyses. Employing a 505(b)(2) regulatory strategy can offer significant benefits, encouraging innovation while offering a faster, more cost-efficient way to drug development. 
Read More